SPRY2 and colonic neoplasm: They showed that the expression of Spry2 positively correlates with the sensitivity of colon cancer cells to the EGFR inhibitor gefitinib and that Spry2 can enhance the response of colon cancer cells to gefitinib by increasing the expression of phosphorylated EGFR, total EGFR, and PTEN.